Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Neupro Patch in Early-stage Parkinson's Disease
NCT02728947Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rotigotine in Parkinson's disease (PD), sponsored by Luye Pharma Group. Primary endpoint: Maximum Plasma Concentration (Cmax) of Rotigotine at 38 days. Started May 2016; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02728947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728947.